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Abstract
Background: ANCA-associated vasculitides (AAV) is a group of rare disorders where 
inflammation and damage of the small blood vessels lead to dysfunction of the sup-
plied organs. In severe flares of the disease patients may require intensive care unit (ICU) 
admission and treatment. The study aims to characterize Polish patients with AAV who 
were admitted to the ICU and compare them to the others.
Methods: An observational, retrospective study based on the POLVAS – registry of Pol-
ish adult patients with AAV was carried out. Patients admitted to the ICU (ICU group) 
were identified and compared with the patients who did not require ICU admission 
(non-ICU group). Characteristics and comparison between groups were made using 
standard statistic descriptive methods.
Results: 30 patients admitted to the ICU were identified among 573 cases included in 
the registry. All patients in the ICU group with available data were ANCA positive. The 
clinical manifestations related to the ICU admission were respiratory, renal and central 
nervous system involvement. The treatment regimen for remission induction was similar 
in both groups. Almost half of the patients in the ICU-group (48.3%) required dialysis, 
whereas in the non-ICU group it was 21.8% (P = 0.01). Infections were also more fre-
quent in the ICU group (72.4% vs. 36.9% P < 0.001). The mortality rate among patients 
who needed ICU treatment was significantly higher when compared to the rest of the 
patients (53.6% vs. 7.8%; P < 0.001).
Conclusions: In the Polish AAV cohort one in twenty patients required ICU admission. 
This group was characterized by multiple organ involvement and high mortality.
Key words: autoimmune diseases, vasculitis, intensive care unit, ANCA, ICU, AAV.
2
Anna Włudarczyk, Grzegorz Biedroń, Krzysztof Wójcik, Zbigniew Zdrojewski, Anna Masiak, Zenobia Czuszyńska, Maria Majdan,  
Radosław Jeleniewicz, Magdalena Krajewska, Mariusz Kusztal, Marek Brzosko, Iwona Brzosko, Alicja Dębska-Ślizień, Hanna Storoniak,  
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ANCA-associated vasculitides (AAV) is a group of 
three disorders in which inflammation and damage 
of the small blood vessels are correlated with the 
presence of antineutrophil cytoplasmic antibodies 
(ANCA). It is considered to be a rare disease with an 
incidence between 12 and 33 cases/1 million popu-
lation/1 year [1]. 
The main clinical types of AAV, based on Cha-
pel Hill classification [2], are granulomatosis with 
polyangiitis (GPA), microscopic polyangiitis (MPA), 
and eosinophilic granulomatosis with polyangiitis 
(eGPA). Details are listed in Table 1.
In rare cases, AAV may be diagnosed based 
on clinical presentation and pathological findings 
without ANCA antibodies present [3]. The main 
pathomechanism consists of an immune-mediated 
inflammatory process that occurs in the walls of 
small vessels. Necrosis of these vessels leads to dys-
function of the supplied organs [3]. The clear causes 
of such an autoimmune reaction are still unknown. 
Clinical manifestation of the AAV can vary from sin-
gle-organ involvement to rapidly progressing sys-
temic disease. Almost every organ can be involved, 
although in the intensive care unit (ICU) setting the 
most important and potentially life-threatening 
manifestations are pulmonary, renal, and neuro-
logical [4].
Pulmonary involvement may lead to diffused 
alveolar haemorrhage with symptoms like cough, 
dyspnoea, and haemoptysis. Laboratory and im-
aging findings include decrease of haemoglobin 
concentration (Hb) in complete blood count (CBC), 
ground-glass opacities in chest X-ray and chest 
computed tomography (CT), blood-stained dis-
charge in bronchoscopy, and hemosiderin loaded 
macrophages in broncho-alveolar lavage (BAL) [5, 
6]. Other common respiratory tract manifestations 
are lung granulomas, bronchi mucosa ulcers, and 
tracheal or subglottic stenosis.
Renal involvement presents as glomerulonephri-
tis with progressive (often rapidly) renal failure. Ini-
tially it can be asymptomatic. Typical laboratory find-
ings are proteinuria, active urinary sediment with red 
blood cells and granular casts, and increased creati-
nine and urea serum concentration [7].
Neurological manifestation typically presents as 
mononeuritis multiplex. Much rarer, but potentially 
far more dangerous, is the central nervous system 
(CNS) involvement, which may lead to ischaemic or 
haemorrhagic stroke [8]. 
Diagnosis
The course of AAV is characterised by flares and 
remissions. In the case of a suspected flare of a dis-
ease, it is important to distinguish the disease from 
the complications of immunosuppressive treat-
ment, like sepsis. Another ICU challenge is the di-
agnosis of the onset of the disease, which can be 
fulminant and life-threatening [9]. When pulmonary 
and renal disfunction coexist, so-called pulmonary-
renal syndrome can be suspected and the diagno-
sis of vasculitis is very probable. Two main causes 
of pulmonary-renal syndrome are AAV and anti-glo-
merular basement membrane disease (Goodpasture 
syndrome – GPS) [10]. Immunological tests, such as 
ANCA screening, as well as rheumatology or clinical 
immunology consult, may allow a diagnosis to be 
made without delay. When possible, obtaining the 
samples for histopathological examination (e.g. kid-
ney biopsy) may be extremely helpful to establish 
the diagnosis and severity of the disease, and hence 
to determine further procedures.
Treatment
Treatment of AAV is based on immunosuppres-
sion with glucocorticosteroids and additional im-
munosuppressants, such as cyclophosphamide or 
rituximab. It is carried out in two stages: intensive 
immunosuppressive treatment to induce disease 
remission, followed by milder maintenance therapy. 
In the ICU setting, in cases of AAV patients, induction 
therapy often requires an aggressive approach [11] 
and can be combined with interventions such as me-
chanical ventilation, continuous renal replacement 
therapy, and therapeutic plasma exchange [12]. 
There are also reports mentioning use of ECMO in 
diffused alveolar haemorrhage due to AAV [13, 14]. 
Patients with AAV admitted to an ICU can also 
suffer from severe infection and sepsis due to im-
munosuppressive treatment. Therefore, thorough 
TABLE 1. Types of ANCA-associated vasculitides
Name Abbreviation Most frequent type of antibodies
Indirect
 immunofluorescence (IIF) test
ELISA test
Granulomatosis with polyangiitis GPA c-ANCA Anti-PR3
Microscopic polyangiitis MPA p-ANCA Anti-MPO
Eosinophilic granulomatosis with polyangiitis eGPA p-ANCA Anti-MPO
ELISA – enzyme-linked immunosorbent assay, p-ANCA – perinuclear immunofluorescence ANCA pattern, c-ANCA – cytoplasmic immunofluorescence ANCA pattern, MPO – myeloperoxidase, 
PR-3 – proteinase 3
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microbiological culture testing and broad-spectrum 
antibiotics when needed are essential.
POLVAS registry
The initiative named POLVAS is the Consortium 
of the Polish Vasculitis Registry, which was estab-
lished to gather data on Polish adult vasculitis pa-
tients. A low incidence of AAV makes it impossible 
for a single centre to design and pursue clinical tri-
als with a substantial number of patients; therefore, 
POLVAS was created by nine centres [15]. 
The presented research is based on the retro-
spective part of the POLVAS registry database. The 
main aim of the study is to characterise Polish pa-
tients with AAV who were admitted to the ICU and 
compare them to those who did not need such 
treatment.
METHODS
This is a multicentre, retrospective, observation-
al, registry-based study on patients diagnosed with 
AAV between 1990 and 2016. 
The study was carried out in accordance with 
the ethical principles of the Declaration of Helsinki 
developed by the World Medical Association. The 
study protocol was approved by the Jagiellonian 
University Bioethics Committee (Krakow, Poland) 
(approval no. 122/6120/25/2016). All POLVAS par-
ticipating centres acquired Local Ethics Committee 
approval. Informed consent was obtained from the 
participants.
All included patients were diagnosed with vas-
culitis according to the American College of Rheu-
matology (ACR) classification criteria [16] and the 
2012 Revised International Chapel Hill Consensus 
criteria [2]. Demographics, laboratory test results, 
clinical data, and treatment details were collected 
from the patients’ medical records using an elec-
tronic form. The characteristics of the entire cohort 
are described in separate manuscripts [17, 18]. The 
presented analysis concerns comparison of the AAV 
patients admitted to the ICU (ICU group) to patients 
who did not require ICU admission (non-ICU group). 
ICU admission was defined in the form as “Severe 
disease flare requiring ICU admission”.
Standard descriptive statistics were used. Nor-
mal distribution of variables was checked by the 
Shapiro-Wilk test, and homogeneity of variances 
was assessed by Levene’s test. To compare the stud-
ied groups the χ2 test (with Yates correction if need-
ed) and Mann-Whitney U test were used. The P-val-
ue < 0.05 was considered as statistically significant, 
modified with Bonferroni correction when multiple 
comparisons were performed. The assumed level of 
significance for multiple comparisons according to 
Bonferroni correction equalled 0.017. 
Calculations were performed with Statistica 
13 software (StatSoft®, Tulsa, OK, USA).
RESULTS
Among 573 cases included in the retrospec-
tive POLVAS database, there were 30 cases (5.24%, 
30/573; 18 males; P = 0.21) who were admitted to 
the ICU. Median time of observation (defined as 
the difference between the date of enrolment to 
the database and the date of the diagnosis) in the 
ICU group equalled three years (2.0–8.0), which was 
similar comparing to the non-ICU group (4 years, 
2.0–8.0; P = 0.98). All patients in the ICU group were 
ANCA positive (in five cases there was no data re-
garding ANCA status), whereas 9% of cases in the 
non-ICU group were ANCA negative. MPA diagno-
sis, p-ANCA presence in IF test as well as anti-MPO 
presence in ELISA assay were associated with the 
risk of ICU admission (P < 0.01). The respiratory sys-
tem was affected in 93.3% of ICU cases. Pulmonary, 
renal, CNS, and eye involvement were significantly 
more frequent in the ICU group (P = 0.03; P = 0.01; 
P < 0.01; P = 0.03). There were also more infections 
and more deaths in the ICU group compared to the 
non-ICU group (both P < 0.01). The details are pre-
sented in Table 2. 
Initial treatment for remission induction was 
analysed. The main trends based on glucocorti-
costeroids and cyclophosphamide were the same 
in both groups; however, the cyclophosphamide 
cumulative dose was significantly higher in the 
non-ICU group, reaching 8.0 g (median: 4.7–15.0 g, 
P < 0.01). Therapeutic plasma exchange was used 
similarly in both groups, but intravenous immuno-
globulins were more frequently given to the pa-
tients who needed ICU treatment during the course 
of disease (17.2% vs. 4.8%, P < 0.01). Almost half of 
the patients in the ICU-group (48.3%) required dialy-
sis treatment at some point, whereas in the non-ICU 
group it was only 21.8% (P = 0.01). Details about the 
treatment are given in Table 3.
DISCUSSION
Generally, ANCA-associated vasculitides are di-
agnosed and treated in specialised internal medi-
cine departments, like rheumatology, nephrology, 
or pulmonology. The majority of the patients do not 
require ICU admission. The data in the registry were 
gathered in the academic centres from across Po-
land, covering about 60% of the Polish population 
[17]. Our study shows that only 5.24% of all investi-
gated AAV patients were admitted to an ICU. This is 
a relatively low number compared with other stud-
ies, in which 12–14% of AAV patients were treated 
in an ICU [19, 20]. This is probably due to the retro-
spective character of the presented part of the reg-
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istry with no follow-up. In addition, ICU admission 
criteria vary across countries [21, 22]. 
Knowledge of the main clinical manifestations 
can be valuable for the intensivists. Published stud-
ies show vasculitis as one of the most frequent au-
toimmune disease in the ICU [12, 23].
It is reported that AAV can have fulminant onset, 
and a significant number of diagnoses – reaching 
10% – were first diagnosed in the ICU [9]. Unfortu-
nately, in our study we lack data on whether the pa-
tients were diagnosed at the ICU. Moreover, infor-
mation on whether it was the first or a subsequent 
flare that resulted in the ICU admission was also not 
included in the registry.
All patients with disease flares requiring ICU 
treatment presented multiorgan involvement. The 
most common manifestations in the ICU group were 
respiratory (93%) and renal (83%), which is consis-
tent with other studies [9, 19, 20, 24]. Respiratory, re-
TABLE 2. The differences between the subgroup of cases who were admitted to the ICU and the subgroup of cases who were not treated in the ICU
Parameter ICU group Non-ICU group P-value
Cases 30 543 –
Men 18/30, 60% 262, 48.3% 0.2101
Median observation (years) 3.0 (2.0–8.0) 4.0 (2.0–8.0) 0.9790
MPA 12/30, 40.4% 93/543, 17.1% MPA/GPA: 0.0047*
MPA/EGPA: 0.0371*
GPA/EGPA: 0.4733*
GPA 17/30, 56.7% 385/543, 70.9%
EGPA 1/30, 3.3% 65/543, 12.0%
p-ANCA presence 13/25, 52.0 % 110/466, 23.6 % 0.0014
c-ANCA presence 12/25, 48.0% 310/466, 66.5% 0.0576
No ANCA 0/25, 0.0% 42/466, 9.0% –
Anti-MPO presence 14/26, 53.8% 119/462, 25.8% 0.018
Anti-PR3 presence 13/26, 50.0% 321/477, 67.3% 0.0690
Cigarette smoking 5/16, 31.3% 143/375, 38.1% 0.5783
Infections 21/29, 72.4% 188/510, 36.9% 0.0001
Deaths 15/28, 53.6% 41/529, 7.8% < 0.0001
Organ involvement
Constitutional symptoms 24/30, 80.0% 455/540, 84.3% 0.5353
Musculo-skeletal system 21/30, 70.0% 307/538, 57.1% 0.1627
Skin 10/30, 33.3% 180/539, 33.4% 0.9944
ENT 16/30, 53.3% 354/543, 65.2% 0.1861
Eye 11/30, 36.7% 108/536, 20.1% 0.0307
Respiratory system 28/30, 93.3% 401/539, 74.4% 0.0335
Cardiovascular system 6/29, 20.7% 83/541, 15.3% 0.4396
Gastrointestinal system 7/30, 23.3% 63/541, 11.6% 0.0574
Renal 26/30, 86.7% 332/539, 61.6% 0.0101
CNS 7/30, 23.3% 42/539, 7.8% 0.0031
Peripheral neurological system 9/30, 30.0% 114/534, 21.3% 0.2642
Statistically significant P-values are shown in bold (assumed level of significance = 0.05)
* Assumed level of significance for multiple comparisons according to Bonferroni correction equals 0.017 
ICU – intensive care unit, MPA – microscopic polyangiitis, GPA – granulomatosis with polyangiitis, EGPA – eosinophilic granulomatosis with polyangiitis, ANCA – antineutrophil cytoplasm antibodies, p-ANCA – perinuclear 
immunofluorescence ANCA pattern, c-ANCA – cytoplasmic immunofluorescence ANCA pattern, MPO – myeloperoxidase, PR-3 – proteinase 3
TABLE 3. Remission induction treatment modalities between ICU and non-ICU groups
Parameter ICU group Non-ICU group P-value
GCs oral 15/29, 51.7% 338/543, 62.2% 0.2560
GCs iv 24/29, 82.8% 402/543, 74.0% 0.2101
CYC 27/29, (93.1%) 435/543, 80.1% 0.1368
RTX 4/29, 13.8% 40/543, 7.4 % 0.3640
TPE 6/29, 20.7% 65/535, 12.1% 0.1769
IVIG 5/29, 17.2% 26/543, 4.8% 0.0039
GS pulses* 24/29, 82.8% 347/475, 73.1% 0.2496
CTX cumulative 
dose in grams (median)
5.0 (2.0–8.0) 8.0 (4.7–15.0) 0.0084
RTX cumulative 
dose in grams (median)
2.4 (1.15–3.75) 2.0 (1.5–2.8) 0.7311
Dialysis 14/29, 48.3% 116/533, 21.8% 0.0010
Statistically significant P-values are bolded (assumed level of significance = 0.05)
* GS pulse was defined as at least one dose of ≥ 500 mg of methylprednisolone (or equivalent)
GCs – glucocorticoids, CYC – cyclophosphamide, RTX – rituximab, TPE – therapeutic plasma exchange,  
IVIG – intravenous immunoglobulins
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nal, and central nervous system manifestations were 
found more often in the ICU-group than in the non-
ICU group. In the study by Demiselle et al., patients 
with AAV treated in an ICU were compared to the 
control group treated in medical units; respiratory 
and CNS involvement were also more common in 
the ICU group, but not renal involvement [4]. It could 
be influenced by the fact that the control group was 
enrolled from the nephrology centres, where renal 
emergencies can be managed outside the ICU. 
The treatment of the AAV has significantly 
changed over time. The last decade has brought 
a better understanding of immunosuppressive 
treatment with reduced doses of glucocorticoste-
roids and cyclophosphamide or new biological 
immunosuppressants, like rituximab. The registry’s 
inclusion period is large; therefore, treatment differ-
ences may result from the state of the knowledge at 
the time as well as the availability of some methods. 
Our study shows that the general remission induc-
tion treatment regimen had no relation to the need 
for ICU treatment. However, a higher cumulative 
dose of cyclophosphamide in the non-ICU group 
could indicate that more aggressive immunosup-
pression can lead to better results, especially be-
cause the mortality was almost seven times higher 
in the ICU group, reaching 53.6%. Such high mor-
tality may also be related to the fact that infections 
were twice as frequent as in the non-ICU group. 
In another study by our team, we showed that 
patients with vasculitides have a worse prognosis 
than other autoimmune disease patients treated in 
the ICU [25]. 
AAV patients who needed ICU admission more 
often required intravenous immunoglobulins (IVIG). 
This may be due to the aforementioned registry’s 
inclusion period, because 20 years ago IVIG therapy 
was more available than therapeutic plasma ex-
change. On the other hand, therapeutic plasma ex-
change frequency was comparable in both groups. 
Recently published results of the PEXIVAS trial by 
Walsh et al. showed that in ANCA-positive patients 
with renal exacerbation or alveolar haemorrhage, 
plasma exchange did not reduce end-stage kidney 
disease incidence or death [26].
Our study has several major limitations. It is 
based on retrospective data gathered in a registry 
and is focused on the overall medical characteristics 
of the cohort. We lack data on specialist ICU proce-
dures and prognostic scales scores. Moreover, we 
were not able to establish from the registry’s dataset 
any details of the ICU admissions. One of the big-
gest disadvantages of POLVAS registry is the scar-
city of data on infectious complications. However, to 
our knowledge, it is the first attempt to estimate the 
problem of AAV in Polish ICUs. Hopefully the pro-
spective part of the POLVAS registry will give more 
details on the matter.
CONCLUSIONS
In the Polish AAV cohort one in 20 patients re-
quired ICU admission. In this group respiratory, 
renal and central nervous system involvement was 
more often observed. The mortality was high. More 
prospective observational studies are needed to 
provide the full characteristics of AAV treated in 
ICUs in the Polish population.
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